A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #113912) in the Treatment of Primary Stage III or IV Epthelial Ovarian, Peritoneal or Fallopian Tube Cancer
Principal Investigator
John Chan MD
Status
Closed to Accrual
Activation Date:09/27/2010
Most Recent Amendment Date:09/26/2016
Date Closed to Accrual:07/01/2013
Disease Site
Gynecologic [GY]
Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if the weekly paclitaxel regimen increases the time until first progression or death (PFS) compared to the every-3-week paclitaxel regimen in women with primary stage II, III or IV epithelial ovarian, peritoneal or fallopian tube cancer who are receiving carboplatin with or without bevacizumab.
Patient Population
Women with primary stage II, III or IV epithelial ovarian, peritoneal or fallopian tube cancer who are receiving carboplatin with or without bevacizumab.
Target Accrual
841